Stada Arzneimittel AG (SAZ)-医療機器分野:企業M&A・提携分析

◆英語タイトル:Stada Arzneimittel AG (SAZ) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8011954
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:37
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Stada Arzneimittel AG (STADA) is a pharmaceutical company that manufacturers low-cost generics and branded over the counter products. The company develops and markets drugs with off-patent active pharmaceutical ingredients, particularly, which are free from commercial property rights. It offers a portfolio of products in various therapeutic categories including pain, women’s health, cardiovascular conditions and diabetes. Some of its major generic products include including Tilidin Naloxon, Atorvastatin, Pantoprazol, Epoetin zeta and Diclofenac. Its major branded products include APO-Go, Grippostad, Snup, Fultium, and Vitaprost. The company operates in more than 30 countries with sales in Germany, Central Europe, CIS/Eastern Europe and Asia-Pacific. STADA is headquartered in Bad Vilbel, Germany.

Stada Arzneimittel AG (SAZ) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Stada Arzneimittel AG, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
Stada Arzneimittel AG, Medical Equipment Deals By Type, 2011 to YTD 2017 6
Stada Arzneimittel AG, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
Stada Arzneimittel AG, Medical Equipment, Deals By Market, 2011 to YTD 2017 8
Stada Arzneimittel AG, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
Stada Arzneimittel AG, Medical Equipment, Deal Details 10
Private Equity 10
Bain Capital and Cinven Partners to Acquire Stada Arzneimittel 10
Partnerships 11
3M Enters Into Licensing Agreement With Stada For Fentanyl Transdermal Patch Technology 11
Lophius Biosciences Enters into Agreement with BL&H 12
Vigilant Biosciences Enters into Distribution Agreement with BL&H 13
Acquisition 14
STADA Arzneimittel Acquires SCIOTEC Diagnostic Technologies for USD19.8 Million 14
Stada Arzneimittel AG – Key Competitors 15
Stada Arzneimittel AG – Key Employees 16
Stada Arzneimittel AG – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Recent Developments 20
Financial Announcements 20
Nov 09, 2017: STADA shows good business development in the third quarter of 2017 and the first nine months 20
Aug 04, 2016: STADA: Excellent business development in the first six months of 2016 23
May 12, 2016: STADA: First quarter of 2016 better than expected – reported key earnings figures substantially higher than previous year – very strong development of the German Generics segment 26
Corporate Communications 28
Jul 04, 2017: STADA Arzneimittel appoints new Chief Executive Officer and Chief Financial Officer – incumbents step down from their positions 28
Apr 24, 2017: Dr. Ralph Grobecker to become Managing Director of STADA’s OTC segment 29
Aug 27, 2016: STADA: Supervisory Board elects Carl Ferdinand Oetker as new Chairman of the Board 30
Jul 06, 2016: Important step on the path to reconfiguring the STADA Supervisory Board 31
Other Significant Developments 33
Aug 03, 2017: STADA shows good operational development in first six months of 2017 33
Jul 11, 2016: STADA approves growth targets for 2019 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37

List of Tables
Stada Arzneimittel AG, Medical Equipment, Key Facts, 2016 2
Stada Arzneimittel AG, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Stada Arzneimittel AG, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
Stada Arzneimittel AG, Medical Equipment Deals By Type, 2011 to YTD 2017 6
Stada Arzneimittel AG, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
Stada Arzneimittel AG, Deals By Market, 2011 to YTD 2017 8
Stada Arzneimittel AG, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
Bain Capital and Cinven Partners to Acquire Stada Arzneimittel 10
3M Enters Into Licensing Agreement With Stada For Fentanyl Transdermal Patch Technology 11
Lophius Biosciences Enters into Agreement with BL&H 12
Vigilant Biosciences Enters into Distribution Agreement with BL&H 13
STADA Arzneimittel Acquires SCIOTEC Diagnostic Technologies for USD19.8 Million 14
Stada Arzneimittel AG, Key Competitors 15
Stada Arzneimittel AG, Key Employees 16
Stada Arzneimittel AG, Subsidiaries 17

★海外企業調査レポート[Stada Arzneimittel AG (SAZ)-医療機器分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • United States Postal Service:企業の戦略的SWOT分析
    United States Postal Service - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Teva Pharmaceutical Industries Ltd (TEVA):製薬・医療:M&Aディール及び事業提携情報
    Summary Teva Pharmaceutical Industries Ltd (Teva) is a pharmaceutical company that carries out the research, development, manufacture and commercialization of generic and specialty medicines. It provides specialty medicines to treat disorders of the central nervous system (CNS), respiratory, cancer, …
  • Trillion Energy International Inc (PKPL):企業の財務・戦略的SWOT分析
    Summary Trillion Energy International Inc (Trillion Energy) formerly Park Place Energy Inc, is an oil and gas company that offers exploration and development of oil and natural gas. The company offers various oil and gas services such as drilling, exploration, development, production, distribution a …
  • Phytel Inc-製薬・医療分野:企業M&A・提携分析
    Summary Phytel Inc (Phytel), a subsidiary of International Business Machines Corporation is an integrated population health management software and solutions provider. The company’s services include reduce total cost of care, prepare for value based care, increase patient engagement, measure quality …
  • First Bancorp. (FBP):企業の財務・戦略的SWOT分析
    First Bancorp. (FBP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • LumiraDx Ltd (LMDX):企業の財務・戦略的SWOT分析
    LumiraDx Ltd (LMDX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Huatai Securities Co., Ltd. (601688):企業の財務・戦略的SWOT分析
    Huatai Securities Co., Ltd. (601688) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Dine Brands Global, Inc. (DIN):企業の財務・戦略的SWOT分析
    Dine Brands Global, Inc. (DIN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Berthold Technologies GmbH & Co. KG:企業の戦略的SWOT分析
    Berthold Technologies GmbH & Co. KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Cleveland BioLabs Inc (CBLI)-医療機器分野:企業M&A・提携分析
    Summary Cleveland BioLabs Inc (Cleveland) is a biopharmaceutical company that develops and commercializes drugs to treat cancer, orphan indications and protect healthy tissues from radiation and chemotherapy. The company’s product includes entolimod, a recombinant protein which acts as an agonist of …
  • Bajaj Allianz General Insurance Company Limited:企業の戦略・SWOT・財務分析
    Bajaj Allianz General Insurance Company Limited - Strategy, SWOT and Corporate Finance Report Summary Bajaj Allianz General Insurance Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, o …
  • ERI Bancaire SA:企業の戦略的SWOT分析
    ERI Bancaire SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • NeoGenomics Inc (NEO):医療機器:M&Aディール及び事業提携情報
    Summary NeoGenomics Inc (NeoGenomics) is a cancer diagnostics and pharma services company that offers diagnostic, prognostic and predictive testing services. The company offers testing services with various technologies such as cytogenetics, fluorescence in-situ hybridization, flow cytometry, immuno …
  • Delta Corporation Limited:企業の戦略・SWOT・財務情報
    Delta Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary Delta Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Valener Inc:企業の戦略的SWOT分析
    Valener Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • JW Pharmaceutical Corp (001060):製薬・医療:M&Aディール及び事業提携情報
    Summary JW Pharmaceutical Corp (JW Pharmaceutical), a subsidiary of JW Holdings Corp is a provider of generic drugs. The company develops and markets analgesics, antipyretics and cold remedy, antidote agents, antimicrobials, anticancer agents, and others. It offers multivitamins and antianemic agent …
  • Intersnack Group GmbH & Co. KG:企業の戦略・SWOT・財務情報
    Intersnack Group GmbH & Co. KG - Strategy, SWOT and Corporate Finance Report Summary Intersnack Group GmbH & Co. KG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Eppendorf AG:医療機器:M&Aディール及び事業提携情報
    Summary Eppendorf AG (Eppendorf) is a life science company that develops, manufactures and sells equipment as well as offers services for handling liquids, samples and cells in laboratories. Its product portfolio includes pipettes, automated pipetting systems, spectrometers, centrifuges, mixers, dis …
  • Inter Pipeline Ltd (IPL):企業の財務・戦略的SWOT分析
    Inter Pipeline Ltd (IPL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Hewlett Packard Enterprise Company:戦略・SWOT・企業財務分析
    Hewlett Packard Enterprise Company - Strategy, SWOT and Corporate Finance Report Summary Hewlett Packard Enterprise Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆